AU2019223906B2 - Methods of use for trisubstituted benzotriazole derivatives - Google Patents

Methods of use for trisubstituted benzotriazole derivatives Download PDF

Info

Publication number
AU2019223906B2
AU2019223906B2 AU2019223906A AU2019223906A AU2019223906B2 AU 2019223906 B2 AU2019223906 B2 AU 2019223906B2 AU 2019223906 A AU2019223906 A AU 2019223906A AU 2019223906 A AU2019223906 A AU 2019223906A AU 2019223906 B2 AU2019223906 B2 AU 2019223906B2
Authority
AU
Australia
Prior art keywords
cancer
cell lymphoma
diffuse large
compound
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019223906A
Other languages
English (en)
Other versions
AU2019223906A1 (en
Inventor
Sung Eun CHOE
Danielle ULANET
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of AU2019223906A1 publication Critical patent/AU2019223906A1/en
Assigned to LES LABORATOIRES SERVIER SAS reassignment LES LABORATOIRES SERVIER SAS Request for Assignment Assignors: AGIOS PHARMACEUTICALS, INC.
Assigned to LES LABORATOIRES SERVIER reassignment LES LABORATOIRES SERVIER Amend patent request/document other than specification (104) Assignors: LES LABORATOIRES SERVIER SAS
Application granted granted Critical
Publication of AU2019223906B2 publication Critical patent/AU2019223906B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019223906A 2018-02-20 2019-02-19 Methods of use for trisubstituted benzotriazole derivatives Active AU2019223906B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2018018679 2018-02-20
USPCT/US2018/018679 2018-02-20
PCT/US2019/018472 WO2019164794A1 (en) 2018-02-20 2019-02-19 Methods of use for trisubstituted benzotriazole derivatives

Publications (2)

Publication Number Publication Date
AU2019223906A1 AU2019223906A1 (en) 2020-09-10
AU2019223906B2 true AU2019223906B2 (en) 2024-11-21

Family

ID=61692059

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019223906A Active AU2019223906B2 (en) 2018-02-20 2019-02-19 Methods of use for trisubstituted benzotriazole derivatives

Country Status (13)

Country Link
US (2) US11717512B2 (https=)
EP (1) EP3755324B1 (https=)
JP (2) JP7434185B2 (https=)
KR (1) KR102861339B1 (https=)
CN (1) CN111757731B (https=)
AU (1) AU2019223906B2 (https=)
BR (1) BR112020016929A8 (https=)
CA (1) CA3091792A1 (https=)
ES (1) ES3038736T3 (https=)
MA (1) MA51897A (https=)
MX (1) MX2020008678A (https=)
TW (1) TWI818954B (https=)
WO (1) WO2019164794A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA48459B1 (fr) * 2017-04-24 2021-09-30 Aurigene Discovery Tech Ltd Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
KR102861339B1 (ko) 2018-02-20 2025-09-19 르 라보레또레 쎄르비에르 삼치환 벤조트리아졸 유도체의 사용 방법
PE20212197A1 (es) * 2018-12-21 2021-11-16 Les Laboratoires Servier Sas Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo
CN111662872A (zh) * 2020-05-06 2020-09-15 西南医科大学附属医院 一种急性t淋巴细胞白血病阿糖胞苷耐药细胞株构建方法
CA3184024A1 (en) * 2020-06-24 2021-12-30 Les Laboratoires Servier Use of a dhodh inhibitor compound in combination cancer therapy
WO2021262874A1 (en) 2020-06-24 2021-12-30 Servier Pharmaceuticals , Llc Use of a dhodh inhibitor compound in combination cancer therapy
KR20230078997A (ko) * 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170224663A1 (en) * 2013-02-25 2017-08-10 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
WO2018197997A1 (en) * 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996035419A1 (en) 1995-05-10 1996-11-14 Pfizer Inc. Combination of methotrexate and tenidap for the treatment of rheumatoid arthritis
US6841561B1 (en) 1999-10-01 2005-01-11 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
JP2003510352A (ja) 1999-10-01 2003-03-18 インスティチュート オブ モレキュラー アンド セル バイオロジー ウイルス媒介性疾病の治療用化合物
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
PL382308A1 (pl) * 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
ATE474833T1 (de) 2004-09-22 2010-08-15 Janssen Pharmaceutica Nv Inhibitoren der wechselwirkung zwischen mdm2 und p53
JP2007015952A (ja) 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
DE102005049953A1 (de) 2005-10-19 2007-04-26 Sanofi-Aventis Deutschland Gmbh Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen
EP2066319B1 (en) 2006-09-08 2012-02-01 F. Hoffmann-La Roche AG Benzotriazole kinase modulators
EP2387568A1 (en) 2009-01-19 2011-11-23 NeuroSearch A/S Novel benzotriazole derivatives useful for the treatment of cns disorders
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
US9316632B2 (en) 2009-03-17 2016-04-19 Marshall University Research Corporation Methods of screening chemotherapeutic agents and treating cancer
WO2010115736A2 (en) 2009-04-02 2010-10-14 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
JP5967827B2 (ja) 2009-12-09 2016-08-10 アジオス ファーマシューティカルズ， インコーポレイテッド Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
CN103476770B (zh) 2010-11-25 2017-02-15 拉蒂欧制药有限责任公司 阿法替尼盐和多晶型物
WO2013049112A1 (en) 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
CN103965133B (zh) 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
PL3139914T3 (pl) 2014-05-08 2023-11-27 Kiora Pharmaceuticals Gmbh Związki stosowane w leczeniu chorób i schorzeń okulistycznych
WO2017037022A1 (en) * 2015-09-01 2017-03-09 Bayer Pharma Aktiengesellschaft Compounds and methods useful for treating or preventing hematological cancers
EP3397625A4 (en) 2015-12-30 2019-12-25 Agios Pharmaceuticals, Inc. TREATMENT OF TUMORS WITH MUTANT ISOCITRATE DEHYDROGENASE
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
US11311548B2 (en) 2017-03-02 2022-04-26 Aslan Pharmaceuticals Pte. Ltd. Cancer therapy
MA48459B1 (fr) 2017-04-24 2021-09-30 Aurigene Discovery Tech Ltd Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
KR102861339B1 (ko) * 2018-02-20 2025-09-19 르 라보레또레 쎄르비에르 삼치환 벤조트리아졸 유도체의 사용 방법
JP7126556B2 (ja) 2018-09-28 2022-08-26 富士フイルム株式会社 シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤
JP7608336B2 (ja) 2018-11-30 2025-01-06 フォンダッツィオーネ・セントロ・サン・ラッファエーレ 中枢神経系原発リンパ腫の併用治療
PE20212197A1 (es) 2018-12-21 2021-11-16 Les Laboratoires Servier Sas Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo
WO2021062157A1 (en) 2019-09-27 2021-04-01 The Rockefeller University Compositions and methods for treating metastatic gastrointestinal cancer
WO2021262874A1 (en) 2020-06-24 2021-12-30 Servier Pharmaceuticals , Llc Use of a dhodh inhibitor compound in combination cancer therapy
CA3184024A1 (en) 2020-06-24 2021-12-30 Les Laboratoires Servier Use of a dhodh inhibitor compound in combination cancer therapy
KR20230078997A (ko) 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170224663A1 (en) * 2013-02-25 2017-08-10 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
WO2018197997A1 (en) * 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors

Also Published As

Publication number Publication date
BR112020016929A8 (pt) 2022-06-28
TWI818954B (zh) 2023-10-21
CN111757731B (zh) 2024-06-25
KR20200123137A (ko) 2020-10-28
KR102861339B1 (ko) 2025-09-19
MA51897A (fr) 2020-12-30
AU2019223906A1 (en) 2020-09-10
JP2023109974A (ja) 2023-08-08
US20240148697A1 (en) 2024-05-09
US11717512B2 (en) 2023-08-08
US20210113531A1 (en) 2021-04-22
JP2021514395A (ja) 2021-06-10
US12290508B2 (en) 2025-05-06
CN111757731A (zh) 2020-10-09
ES3038736T3 (en) 2025-10-14
EP3755324B1 (en) 2025-07-30
BR112020016929A2 (pt) 2020-12-15
CA3091792A1 (en) 2019-08-29
WO2019164794A1 (en) 2019-08-29
EP3755324A1 (en) 2020-12-30
MX2020008678A (es) 2020-09-25
TW201938543A (zh) 2019-10-01
EP3755324C0 (en) 2025-07-30
JP7434185B2 (ja) 2024-02-20

Similar Documents

Publication Publication Date Title
AU2019223906B2 (en) Methods of use for trisubstituted benzotriazole derivatives
CN102844023B (zh) Cdc7激酶抑制剂以及其用途
AU2016213972B2 (en) Combinations of IRS/Stat3 dual modulators and anti-cancer agents for treating cancer
KR20250151577A (ko) Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클
JP2020517652A (ja) 併用療法
JP2015536986A (ja) 併用療法
TWI884912B (zh) 喹啉酮類似物及其鹽、組合物及其使用方法
KR20140072028A (ko) Pi3k- 및 mek-억제제의 상승작용적 조합물
CA2760179A1 (en) Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound
TW202329969A (zh) 用於治療急性髓系白血病的ＦＬＴ３抑制劑和Ｂｃｌ－３抑制劑的治療有效組合
AU2014279721A1 (en) Pharmaceutical combinations of a PI3K inhibitor and a microtubule destabilizing agent
KR20240158972A (ko) 소세포 폐암의 치료 방법
TW202021591A (zh) B細胞惡性腫瘤之治療
HK40043674A (en) Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
HK40043674B (en) Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
KR102687556B1 (ko) 종양 전이를 억제하는 방법
KR102875039B1 (ko) 1,2-나프토퀴논 유도체 화합물을 포함하는 고형암 또는 혈액암의 예방 또는 치료용 약학 조성물
EP1547596A1 (en) Medicinal composition and method for treating malignant tumor and utilization thereof
WO2025070603A1 (ja) 血液がんの新規併用療法
HK40042000B (zh) 苯并氧氮杂䓬恶唑烷酮化合物及其使用方法
HK40042521B (zh) 苯并氧氮杂䓬恶唑烷酮化合物及其使用方法

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: LES LABORATOIRES SERVIER SAS

Free format text: FORMER APPLICANT(S): AGIOS PHARMACEUTICALS, INC.

HB Alteration of name in register

Owner name: LES LABORATOIRES SERVIER

Free format text: FORMER NAME(S): LES LABORATOIRES SERVIER SAS

FGA Letters patent sealed or granted (standard patent)